Korro Bio, Inc.
$14.28
▲
10.67%
2026-04-21 07:46:01
www.korrobio.com
NCM: KRRO
Explore Korro Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$207.54 M
Current Price
$14.28
52W High / Low
$55.89 / $5.2
Stock P/E
—
Book Value
$5.46
Dividend Yield
—
ROCE
-85.99%
ROE
-1.11%
Face Value
—
EPS
$-12.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
58
Beta
2.43
Debt / Equity
84.54
Current Ratio
6.9
Quick Ratio
6.9
Forward P/E
-1.67
Price / Sales
28.61
Enterprise Value
$151.21 M
EV / EBITDA
-1.82
EV / Revenue
23.66
Rating
None
Target Price
$20
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 2. | TransCode Therapeutics, Inc. | $8.88 | — | $8.07 M | — | -334.68% | -17.63% | $22.03 / $6.08 | $1.71 |
| 3. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
| 4. | Champions Oncology, Inc. | $6.08 | — | $84.36 M | — | 57.07% | -47.59% | $9.63 / $5.5 | $0.31 |
| 5. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 6. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
| 7. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.29 M | 1.09 M | 1.46 M | 2.55 M | 2.27 M | — |
| Operating Profit | -15.88 M | -19.24 M | -27.2 M | -25.02 M | -23.04 M | — |
| Net Profit | -50.04 M | -18.06 M | -25.77 M | -23.39 M | -21.2 M | — |
| EPS in Rs | -3.47 | -1.25 | -1.79 | -1.62 | -1.47 | -2.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.39 M | 2.27 M | 0 M | 0 M |
| Operating Profit | -87.34 M | -91.91 M | -84.53 M | -59 M |
| Net Profit | -117.26 M | -83.58 M | -81.17 M | -58.03 M |
| EPS in Rs | -8.13 | -5.8 | -5.63 | -4.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 113.51 M | 226.24 M | 221.66 M | 73.74 M |
| Total Liabilities | 62.07 M | 65.83 M | 51.75 M | 172.77 M |
| Equity | 51.44 M | 160.41 M | 169.91 M | -99.03 M |
| Current Assets | 82.37 M | 131.53 M | 172.73 M | 57.08 M |
| Current Liabilities | 11.94 M | 14.96 M | 19.48 M | 8.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -78.56 M | -60.07 M | -67.28 M | -53.65 M |
| Investing CF | 43.99 M | -123.35 M | 11.16 M | 11.06 M |
| Financing CF | 0.69 M | 69.36 M | 187.76 M | 0.02 M |
| Free CF | -79.08 M | -77.98 M | -75.12 M | -58.86 M |
| Capex | -0.52 M | -17.9 M | -7.84 M | -5.21 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -2.97% | -39.87% | — | — |
| Profit Margin % | -3680.36% | — | — | — |
| Operating Margin % | -4047.12% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -3890.14% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-11-06 | 1:0.02 |